Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma

NCT00336063 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00336063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 3, 2006
Completion date
March 31, 2027
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, recurrent nasopharyngeal keratinizing squamous cell carcinoma, recurrent nasopharyngeal undifferentiated carcinoma, stage iv nasopharyngeal keratinizing squamous cell carcinoma ajcc v7, stage iv nasopharyngeal undifferentiated carcinoma ajcc v7